11:57 AM EST - ProMetic Life Sciences Inc. : announced today that an orphan drug designation status has been granted for its plasma purified human plasminogen drug to ProMetic BioTherapeutics, Inc., its U.S. based subsidiary, by the American Food and Drug Administration ("FDA"). The orphan drug designation is for the treatment of hypoplasminogenemia, or type I plasminogen deficiency ("T1PD"). ProMetic is currently developing a systemic formulation for the treatment of T1PD in partnership with Hematech Biotherapeutics Inc. and has already successfully scaled up the manufacturing process. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.025 at $0.43.
